Chromosomal aberrations and their role in the transformation of chronic lymphocytic leukaemia in the era of BCR inhibitors treatment

Czech version

Authors: H. Urbánková; L. Krůzová; M. Holzerová; R. Urbanová; P. Turcsányi; T. Papajík
Authors‘ workplace: Hemato-onkologická klinika Lékařské fakulty Univerzity Palackého a Fakultní nemocnice Olomouc
Published in: Transfuze Hematol. dnes,26, 2020, No. 1, p. 30-34.
Category: Review/Educational Papers

Overview

Použití inhibitorů BCR signalizace znamenalo obrovský pokrok v léčbě pacientů s relabovanou/refrakterní (R/R) chronickou lymfocytární leukemií (CLL), zejména s prognosticky negativními cytogenetickými změnami. Navzdory tomu však stále dochází u části pacientů k transformaci do agresivnějšího lymfoproliferativního onemocnění, tzv. Richterova syndromu (RS). Účinná léčba pacientů s RS v současné době není k dispozici. Pochopení molekulární podstaty transformace je kritické pro vývoj nových léčiv a jejich kombinací.

Keywords:

TP53 – chronic lymphocytic leukaemia (CLL) – Richter syndrome (RS) – CDKN2A – complex karyotype

Sources

1. Rossi D, Gaidano G. Richter syndrome: molecular insights and clinical perspectives. Hematol Oncol. 2009;27(1):1–10.

2. Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues, revised 4²

^th edition. Lyon: International Agency for Research on Cancer (IARC); 2017. 216–221 p.

3. Maddocks KJ, Ruppert AS, Lozanski G, et al. Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia. JAMA Oncol. 2015;1(1):80–87.

4. Jain P, Keating M, Wierda W, et al. Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. Blood. 2015;125(13):2062–2067.

5. Ahn IE, Underbayev C, Albitar A, et al. Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia. Blood. 2017;129(11):1469–1479.

6. Timar B, Fulop Z, Csernus B, et al. Relationship between the mutational status of VH genes and pathogenesis of diffuse large B-cell lymphoma in Richter’s syndrome. Leukemia. 2004;18(2):326–330.

7. Rossi D, Spina V, Deambrogi C, et al. The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. Blood. 2011;117(12):3391–3401.

8. Brecher M, Banks PM. Hodgkin’s disease variant of Richter’s syndrome. Report of eight cases. Am J Clin Pathol. 1990;93(3):333–339.

9. Mao Z, Quintanilla-Martinez L, Raffeld M, et al. IgVH mutational status and clonality analysis of Richter’s transformation: diffuse large B-cell lymphoma and Hodgkin lymphoma in association with B-cell chronic lymphocytic leukemia (B-CLL) represent 2 different pathways of disease evolution. Am J Surg Pathol. 2007;31(10):1605–1614.

10. Jain P, O’Brien S. Richter’s transformation in chronic lymphocytic leukemia. Oncology (Williston Park). 2012;26(12):1146–1152.

11. Rossi D, Gaidano G. Richter syndrome: pathogenesis and management. Semin Oncol. 2016;43(2):311–319.

12. Fabbri G, Khiabanian H, Holmes AB, et al. Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome. J Exp Med. 2013;210(11):2273–2288.

13. Parikh SA, Kay NE, Shanafelt TD. How we treat Richter syndrome. Blood. 2014;123(11):1647–1657.

14. Rossi D, Spina V, Gaidano G. Biology and treatment of Richter syndrome. Blood. 2018;131(25):2761–2772.

15. Xiao W, Chen WW, Sorbara L, et al. Hodgkin lymphoma variant of Richter transformation: morphology, Epstein-Barr virus status, clonality, and survival analysis-with comparison to Hodgkin-like lesion. Hum Pathol. 2016;55:108–116.

16. Rossi D, Cerri M, Capello D, et al. Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome. Br J Haematol. 2008;142(2):202–215.

17. Doubek M, Špaček M, Pospíšilová Š, et al. Doporučení pro diagnostiku a léčbu chronické lymfocytární leukemie (CLL) – 2018. Transfuze Hematol Dnes. 2018;24(3):208–220.

18. Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343(26):1910–1916.

19. Chigrinova E, Rinaldi A, Kwee I, et al. Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome. Blood. 2013;122(15):2673–2682.

20. Burger JA, Landau DA, Taylor-Weiner A, Bozic I, Zhang H, Sarosiek K, et al. Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. Nat Commun. 2016;7:11589.

21. Khan M, Siddiqi R, Thompson PA. Approach to Richter transformation of chronic lymphocytic leukemia in the era of novel therapies. Ann Hematol. 2018;97(1):1–15.

22. Ouillette P, Fossum S, Parkin B, et al. Aggressive chronic lymphocytic leukemia with elevated genomic complexity is associated with multiple gene defects in the response to DNA double-strand breaks. Clin Cancer Res. 2010;16(3):835–847.

23. Edelmann J, Holzmann K, Miller F, et al. High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations. Blood. 2012;120(24):4783–4794.

24. Papajík T, Urbanová R, Turcsányi P. Ohlédnutí za čtvrtstoletím léčby chronické lymfocytární leukemie. Transfuze Hematol Dnes. 2019;25(1):72–80.

25. Miller CR, Ruppert AS, Heerema NA, et al. Near-tetraploidy is associated with Richter transformation in chronic lymphocytic leukemia patients receiving ibrutinib. Blood Adv. 2017;1(19):1584–1588.

26. Urbánková H, Krůzová L, Holzerová M, et al. Chromozomové a genomické změny u pacientů s transformací chronické lymfocytární leukemie léčených inhibitory BCR signalizace. Sborník abstrakt XXXIII Olomoucké hematologické dny; 2019 26.–28. 5. 2019; Olomouc, Česká Republika. Olomouc: Univerzita Palackého v Olomouci; 2019.

27. Woyach JA, Ruppert AS, Guinn D, et al. BTK(C481S)-mediated resistance to ibrutinib in chronic lymphocytic leukemia. J Clin Oncol. 2017;35(13):1437–1443.